We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Genetic "Hotspots” Tailor Therapies for Bowel Cancer Treatment

By LabMedica International staff writers
Posted on 22 Feb 2010
A new study has identified the repetition frequency of new genetic "hotspots,” which could help doctors offer personalized therapies for bowel cancer patients.

Researchers at the University of Dundee (United Kingdom) carried out a genetic analysis on 106 bowel cancer tumor samples to search for the frequency of known faults in a key gene called K-Ras--an important protein which acts as an "on-off switch” in cells to control growth--since it is already known that in some bowel cancers the K-Ras gene is faulty, leaving the switch permanently "on.” The researchers screened the colorectal tumors for additional K-Ras mutation phenotypes and Ras guanine triphosphate (GTP)-ase activating assays and gene and pathway changes induced by individual K-Ras mutants. More...


The researchers found that besides the current K-Ras "hotspots” in codons 12, 13, and 61, four additional K-Ras mutations (Leu19Phe, Lys117Asn, Ala146Thr, and Arg164Gln) were identified, most commonly at codon 146. The researchers additionally identified a new K-Ras gene amplification event, present in approximately 2% of tumors. According to the researchers, the study suggests that as many as 33% of bowel cancer patients have a K-Ras fault. As a result, they recommend future mutation screening to facilitate optimal patient selection for treatment with Epidermal Growth Factor Receptor (EGFR)-targeted therapies should therefore be extended to codon 146, and in addition should consider the unique molecular signatures associated with individual K-Ras mutations. The study was published early online on February 9, 2010, in the British Journal of Cancer.

"These results highlight additional gene faults which potentially could be tested for in bowel cancer patients to determine which people will respond best to which drugs,” said lead author Gillian Smith, Ph.D. "The next stage is to develop effective tests to screen for these mutation 'hotspots' to help doctors to plan the most effective treatment strategies for bowel cancer patients - and this will encourage scientists to also focus their efforts on finding new treatments for patients with faulty K-Ras genes to give them more options.”

Targeted therapies are drugs that are designed to treat cancer cells while minimizing damage to normal, healthy cells. The drugs interfere with specific pathways involved in cancer cell growth or survival, such as blocking growth signals and reducing the blood supply to cancer cells; others stimulate the immune system to recognize and attack the cancer cell. The two types of targeted therapy that are currently being used for colorectal cancer are EGFR inhibitors--such as panitumumab, a monoclonal antibody that binds to and blocks EGFR--and antiangiogenic drugs.

Related Links:

University of Dundee



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.